Maurie Markman, MD, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
Maurie Markman, MD, president of medicine and science at the Cancer Treatment Centers of America, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
For example, Markman says that the development of platinum-based chemotherapies such as paclitaxel started in ovarian cancer. Over time, this development became increasingly important in other cancers and tumor types as well.
Five years ago, treatments from ovarian cancer were not being used in areas such as lung cancer, but currently, these effective chemotherapies, targeted therapies, and immunotherapies are being used in a number of cancer types for chronic management, Markman adds.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More